Zero ischemia robotic-assisted partial nephrectomy in Alberta: Initial results of a novel approach

Ellen Forbes, MD,* Douglas Cheung, BMSc,† Adam Kinnaird, MD,* Blair St. Martin, MD*

*Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB; †Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB

Abstract

Introduction: Partial nephrectomy remains the standard of care in early stage, organ-confined renal tumours. Recent evidence suggests that minimally invasive surgery can proceed without segmental vessel clamping. In this study, we review our experience at a Canadian centre with zero ischemia robotic-assisted partial nephrectomy (RAPN).

Methods: A retrospective chart review of zero ischemia RAPN was performed. All surgeries were consecutive partial nephrectomies performed by the same surgeon at a tertiary care centre in Northern Alberta. The mean follow-up period was 28 months. These outcomes were compared against the current standards for zero ischemia (as outlined by the University of Southern California Institute of Urology [USC]).

Results: We included 21 patients who underwent zero ischemia RAPN between January 2012 and June 2013. Baseline data were similar to contemporary studies. Twelve (57.1%) required no vascular clamping, 7 (33.3%) required clamping of a single segmental artery, and 2 (9.5%) required clamping of two segmental arteries. We achieved an average estimated blood loss of 158 cc, with a 9.2% average increase in creatinine postoperatively. Operating time and duration of hospital stay were short at 153 minutes and 2.2 days, respectively.

Conclusion: Zero ischemia partial nephrectomy was a viable option at our institution with favourable results in terms of intra-operative blood loss and postoperative creatinine change compared to results from contemporary standard zero ischemia studies (USC). To our knowledge, this is the first study to review an initial experience with the zero ischemia protocol in robotic-assisted partial nephrectomies at a Canadian hospital.

Introduction

Malignant renal neoplasms are a significant cause of morbidity and mortality worldwide.1,2 Treatment remains largely surgical; open, laparoscopic, and robotic partial nephrec-
studied, including transfusion rate, operation (OR) time, length of hospital stay, 90-day complication rate, and hemoglobin concentration changes.

**Technical application of the zero ischemia protocol**

We adopted a lateral camera port placement with the robotic camera port directly over the midpoint of the kidney. We used a 0° lens in the majority of cases; however, in some cases where further visualization over the upper pole was required, we added a 30° lens.

Complete mobilization of the kidney within Gerota’s fascia was then performed in all cases except for small anterior exophytic lesions. This involved a longitudinal incision along the medial aspect of the anterior border of the kidney over Gerota’s fascia and folding Gerota’s fascia behind the kidney after fully mobilizing it. Posterior tumours were approached with complete mobilization of the kidney, and then 180° renal mobilization such that the tumours were presented in an anterior fashion for dissection.

At the time of tumour resection (Fig. 2), we used controlled hypotension with a target systolic blood pressure (sBP) between 80 and 100 mmHg. Adherence to this principle was uniformly adopted by our anesthetic team unless the patient had prior significant cardiopulmonary risk factors precluding this level of hypotension. In all 21 cases, this period of hypotension was less than 30 minutes. Secondly, at the time of tumour resection, we increased the pneumoperitoneum to 20 mmHg to control the venous ooze at the tumour bed. Aspiration of blood was also minimized as this decreased the pneumoperitoneum, leading to further venous ooze. Selective suctioning along the resection point of the tumour bed was utilized to facilitate dissection and resection. Any large blood vessel encountered was controlled with bipolar cautery through the fenestrated bipolar device. Additionally, the third robotic arm applied direct pressure on any significant bleeding vessels at the tumour bed.

Once the resection was complete, the individual bleeding points were selectively ligated with a 4-0 Vicryl on an SH needle. The remaining closure of the tumour bed was performed with running 3-0 PDS sutures controlled on either end with a 12 mm Hem-o-lok clip and tensioned until hemostasis was achieved. We did not utilize compressive buttress sutures to minimize damage to the normal parenchyma. In 9 cases, we used Surgicel (Ethicon Inc.) to facilitate hemostasis.

Finally, our initial longitudinal incision in Gerota’s fascia was closed in a watertight fashion as a complement to the reconstruction, obviating the need for a peri-renal drain which was not routinely placed. Our outcomes were then compared against the current standard for zero ischemia by initial studies.

**Results**

Between January 2012 and June 2013, there were 21 patients who underwent zero ischemia RAPN and included in this study (n = 21). All baseline demographic data were similar...
to that originally proposed by other RAPN studies. The mean age was 56, 62% of patients were male, 19% severely obese, and the average Charlson comorbidity score was 2 (Table 1).

Baseline information regarding tumour characteristics was also not significant, controlling for size, stage, and location. The average tumour size was 3.1 cm, and tumour staging of T1a was 76.2% (16/21) and T1b was 23.8% (5/21) (Table 2).

Of the 21 patients, 12 (57.1%) required no vascular clamping whatsoever, 7 (33.3%) required clamping of a single segmental artery and 2 (9.5%) required clamping of two segmental arteries. No patients required hilar clamping or were converted to open procedures. We achieved an average estimated blood loss of 158 cc, with a 9.2% average increase in creatinine postoperatively. Operating time and duration of hospital stay were short at 153 minutes and 2.2 days, respectively (Table 3).

We also examined pathological findings, including percentage clear cell renal cell carcinoma (RCC), papillary RCC, oncocytoma, angiomylipoma, Furhman grading, and surgical margin status (Table 4).

**Discussion**

Our findings suggest zero ischemia partial nephrectomy is a viable option at our institution with favourable results in terms of intra-operative blood loss and postoperative creatinine change compared to results from contemporary standard zero ischemia studies (University of Southern California Institute of Urology [USC]). Furthermore, we observed a favourable trend towards decreased hospital stay and complication rates.

In applying the zero ischemia protocol, we found that 7/21 (33.3%) of our patients required clamping of one segmental artery and 2/21 (9.5%) required clamping of two segmental arteries. The remaining (12/21, 57.1%) required no vascular clamping. Compared to published results from USC Institute of Urology, we recorded favourable rates in all outcome measures of average estimated blood loss (158 vs. 206 cc), increases in creatinine (9.2% vs. 18%), OR time (153 vs. 264 minutes), and length of stay (2.2 vs. 3.9 days). This included zero operations requiring blood transfusion (at USC 21% of patients required blood transfusion), no intra-operative complications, 14% postoperative complications within 90 days (at USC 23%), and at the end of follow-up (mean 28 months), there was no evidence of cancer recurrence. Notably, there was no conversion to hilar clamping, no laparoscopic to open conversion, and no lost kidneys (Table 5).

These results suggest very limited morbidity and subsequent mortality in applying the zero ischemia technique at our institution. Given that decreased blood loss is often cited as a reason to pursue hilar clamping, relatively small amounts of blood loss (mean 158 cc in our experience) is quite reassuring.

Furthermore, there was a minimal increase in creatinine after surgery in our patients (mean 9.2%), indicating little effect on renal function postoperatively. Notably, postoperative renal function is multifactorial relative to preoperative function, preserved renal mass, and intra-operative renal ischemia. Ischemia time, known to contribute to short-term acute renal failure and long-term end-stage renal disease, is the only surgically modifiable risk factor in patients presenting for partial nephrectomy. Thus, limiting this ischemic time is imperative for preserving renal function and minimizing cellular damage to the kidneys. Because of improved vascular micro-dissection techniques that allow for little to
no ischemia time, zero ischemia partial nephrectomies have demonstrated promising results in both our patient set and in contemporary studies with no intra-operative hilar clamping.15,18,25

At this point, our results suggest that we are achieving favourable outcomes compared to those proposed by contemporary landmark studies.18,20,25 Consistently across renal function, blood loss and ancillary outcome measures, our results propose that our application of the zero ischemia technique may be a viable and effective alternative, if not an improvement, on the existing practice. In particular, we feel that a number of key points are crucial to improved perioperative blood loss, including the use of controlled hypotension. As well, careful attention to optimizing the pneumoperitoneum limited venous oozing at the tumour bed during the dissection and resection. Furthermore, ensuring a watertight closure of Gerota’s fascia played a role in minimizing perioperative and postoperative blood loss, as well as controlling and preventing urine leak. In our experience, the robotic surgical system with 3 manipulating arms plus the camera port facilitates our technique by utilizing the third arm to control active hemostasis during surgical dissection and resection. Finally, individual patient factors should always be carefully assessed prior to proceeding with zero ischemia. For example, increased venous pressures in portal hypertension may overcome the pneumoperitoneum and increase blood loss, and should be a consideration for hilar clamping.

Notably, our experience represents an entirely RAPN series at a Canadian centre versus a combination LPN (74%) and RAPN (26%) series previously presented in the initial study.20 Continued practice and research in this area will be necessary to demonstrate long-term outcomes in renal function and cancer control.19

Given that these are the preliminary findings at our institution, our conclusions are limited by a small sample size and relatively short-term follow-up with outcomes data. In the future, we will need to establish a database to assess long-term outcomes in the continued application of this technique compared against our laparoscopic, robotic, and open partial nephrectomy outcomes. Finally, other future research on complex and hilar tumour management through vascular micro-dissection will also be important to study.26,27

### Conclusion

To our knowledge, we are the first study to review our initial experience with the zero ischemia protocol in robotic-assisted partial nephrectomies at a Canadian hospital. Our findings demonstrated favourable outcomes compared to those presented in contemporary studies. We also observed a trend towards decreased hospital stay, blood loss, and complication rates than previously described. Further long-term research will need to confirm our preliminary findings.

### Competing interests

Authors declare no competing financial or personal interests.

This paper has been peer-reviewed.

### References


### Table 5. Edmonton versus USC outcomes

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Edmonton (RAPN only)</th>
<th>USC (LPN and RAPN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average estimated blood loss (cc)</td>
<td>158</td>
<td>206</td>
</tr>
<tr>
<td>Creatinine increase</td>
<td>9.2%</td>
<td>18%</td>
</tr>
<tr>
<td>Operating room time (minutes)</td>
<td>153</td>
<td>264</td>
</tr>
<tr>
<td>Length of stay (days)</td>
<td>2.2</td>
<td>3.9</td>
</tr>
<tr>
<td>Blood transfusions</td>
<td>0%</td>
<td>21%</td>
</tr>
<tr>
<td>Postoperative complications within 90 days</td>
<td>14%</td>
<td>23%</td>
</tr>
</tbody>
</table>

RAPN: robotic-assisted partial nephrectomy
Forbes et al.


Correspondence: Dr. Blair St. Martin, Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB; stmartin@ualberta.ca